T

Thalia Therapeutics

Thalia Therapeutics is a UK-based biotechnology company specializing in RNA-based medical solutions. The company has raised €3.1 million to accelerate its clinical-stage oncology and RNA-based pipeline, including the acquisition of Sanmirna Therapeutics, which brings a microRNA therapeutic candidate into its portfolio.

Total raised
Undisclosed
tracked to date
Latest round
€3.1 Million
Jun 28, 2026
Known investors
1
led by Premier Miton

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United Kingdom.

Claim this profile →

🏆 Featured in Datapile’s Q2 2026 UK Funding Report

Read the Q2 2026 UK report →
Add this badge to your site
<a href="https://datapile.co/reports/q2-2026-uk-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 UK Funding Report</a>

Funding history

  1. 1
    €3.1 MillionJun 28, 2026

    Led by Premier Miton

    Announcement ↗

Founder

D
Dr. David Solomon
CEO

Investors in Thalia Therapeutics

Backers from this company's tracked funding rounds.

  • PPremier MitonLead investorVC firm

Thalia Therapeutics in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile

Thalia Therapeutics — Health startup in United Kingdom | Datapile